statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024. The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first...

MorphoSys AG Reports First Quarter 2024 Financial Results

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

Futures Rise, Yen Downgraded To Banana Republic Currency After Another Rollercoaster Session

 US equity futures swung between gains and losses and traded near session highs as US traders...

Futures Rise, Yen Downgraded To Banana Republic Currency After Another Rollercoaster Session

The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned...

MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

Morphosys (MOR) has released an update. MorphoSys AG has released a notification of major holdings, revealing that Barclays PLC now holds new votin...

Barclays PLC Adjusts Stake in MorphoSys AG

In this article, we will take a look at the 11 oversold blue chip stocks to buy right now. To skip our analysis of the recent trends and market activity, you can go directly to see the 5 Oversold...

11 Oversold Blue Chip Stocks to Buy Right Now

MorphoSys AG (NASDAQ:MOR  Get Free Report) has been given an average rating of Hold by the eight brokerages that are currently covering the stock, Marketbeat Ratings reports...

Brokerages Set MorphoSys AG (NASDAQ:MOR) Price Target at $11.78

Syndax Pharmaceuticals SNDX stock rose 7.6% on Mar 27 after it announced a day before that the FDA had granted a priority review to its new drug application (NDA) for pipeline candidate revumenib...

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

This is a signal that MOR's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

MorphoSys AG (MOR, $18.15) RSI Indicator left the overbought zone on March 25, 2024

This is a signal that MOR's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

MorphoSys AG (MOR, $18.19) Stochastic Oscillator left the overbought zone on March 22, 2024

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Watchers	635
52-Wk Low	$4.19
52-Wk High	$18.31

Volume	203,530.00
52-Wk High	$18.31
52-Wk Low	$4.19

MOR MorphoSys AG ADR

About

Feed

News

Sentiment

Fundamentals